|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Subscriptions receivable | ||||||||||||||||||||
| Prepaid expenses, taxes and other receivables | ||||||||||||||||||||
| Clinical trial deposit | ||||||||||||||||||||
| Stock subscription receivable | ||||||||||||||||||||
| Deposits, planned business acquisition (note 1) | ||||||||||||||||||||
| Stock subsciption receivable | ||||||||||||||||||||
| Advances to acquisition target (note 1) | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating right-of-use assets | ||||||||||||||||||||
| Other noncurrent assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| In-process research and development | ||||||||||||||||||||
| Revolving credit facility debt issuance costs, net | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Related party payables | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total related party payables | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Kineta severance promissory notes | ||||||||||||||||||||
| Revolving credit facility - interest and annual fee | ||||||||||||||||||||
| Revolving credit facility - commitment fee to be settled in shares | ||||||||||||||||||||
| Note Payable assumed from Kineta Merger | ||||||||||||||||||||
| Holdback liability | ||||||||||||||||||||
| Lease liabilities, current | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Milestone payment liability | ||||||||||||||||||||
| Milestone payment liability | ||||||||||||||||||||
| Long-term Liabilities: | ||||||||||||||||||||
| Convertible notes payable, net | ||||||||||||||||||||
| Revolving credit facility borrowings, related party | ||||||||||||||||||||
| Lease liability, long term | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders's Equity: | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Preferred Stock Series A | ||||||||||||||||||||
| Preferred Stock Series C | ||||||||||||||||||||
| Preferred Stock Series A, A 1, and B | ||||||||||||||||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized; 63,682,528 and 59,336,104 shares issued and outstanding as of June 30, 2026 and December 31, 2025. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Due from stockholders | ||||||||||||||||||||
| Officer | ||||||||||||||||||||
| Total due from stockholders | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity |
Loading...
